- Repare Therapeutics (RPTX, Financial) announces six abstracts for presentation at the AACR Annual Meeting 2025.
- Two abstracts will be presented as mini-oral presentations, with four additional poster presentations.
- Research focuses on innovative cancer treatments, including precision oncology and genetic instability therapy.
Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage company specializing in precision oncology, has had six abstracts accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025. The event will be held in Chicago, Illinois, from April 25-30, 2025.
The company will deliver two mini-oral presentations. The first, presented by Dr. Alison M. Schram from Memorial Sloan Kettering Cancer Center, explores the efficacy and safety of combining lunresertib, a PKMYT1-inhibitor, with camonsertib, an ATR-inhibitor, in treating ovarian and endometrial cancers. This presentation is scheduled for April 29 and will cover initial results from the Phase I MYTHIC study (NCT04855656).
The second mini-oral presentation, to be delivered by Dr. John M. Maris from the Children's Hospital of Philadelphia, focuses on the PLK4 inhibitor RP-1664 and its effects on neuroblastoma models in preclinical settings. This presentation is scheduled for April 27.
Additionally, Repare Therapeutics will present four posters detailing further research advancements. These include insights into the dual mechanisms of sensitivity to PLK4 inhibition in neuroblastoma and the targeting of CCNE1 amplification in gastric cancer, among others.
The company continues to leverage its proprietary SNIPRx® platform in the pursuit of targeted cancer therapies addressing genomic instability and DNA damage repair. Each presentation will be accessible on the scientific resources page of the Repare Therapeutics website at the relevant session times.
